Does the FDA guidance differ by age group

DISCLOSURE: Voshell's Pharmacy is a licensed compounding pharmacy that prepares and sells compounded medications by prescription. As a provider of competing products, our perspective may be influenced by our professional and commercial interests.

According to FDA.gov, the FDA does not create different hormone therapy rules for different ages. The official guidance applies uniformly. What changes with age is how clinicians apply that guidance, because a woman's risks shift over time.

How FDA Guidance Works

According to FDA.gov, the FDA's universal message is to use the lowest effective dose for the shortest duration needed to treat menopausal symptoms. This applies to all ages. According to FDA.gov, the FDA does not set age cutoffs, preferred ages, or age-based restrictions in its labeling.

The reason is straightforward: the FDA regulates the medication itself, not the patient population. They approve products and provide safety labeling, and then a qualified prescriber tailors treatment individually. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing and are prepared by a licensed pharmacist only in response to a valid prescription for an individual patient. This page primarily discusses commercially available hormone therapy products.

How Age Alters Clinical Decision-Making (Even Though FDA Rules Don't Change)

• Under age 60 or within 10 years of menopause: This group generally has a lower baseline risk of heart disease and stroke. Because of that, a qualified prescriber may feel more comfortable using systemic hormones when symptoms are strong. According to NAMS, this reflects modern research rather than an FDA age rule.
• Over age 60 or more than 10 years since menopause: According to the FDA-approved prescribing information for hormone therapy products, baseline risks for blood clots, stroke, heart disease, and dementia rise naturally with age. Hormones do not automatically become unusable, but they interact with an older cardiovascular system differently — which is why a qualified prescriber reviews risks more carefully. These are clinical judgments, not FDA requirements.
• Any age needing vaginal estrogen: Local vaginal estrogen, used for dryness or painful intercourse, is associated with very low systemic absorption at any age. According to the FDA-approved prescribing information for locally applied estrogen products, labeling requirements are the same, but a qualified prescriber may apply them flexibly across all ages.

What the FDA Actually Emphasizes

• Use the lowest dose that controls symptoms.
• Reassess regularly. According to FDA.gov, the FDA expects ongoing evaluation, not automatic continuation indefinitely.
• Know the risks listed on the label. According to the FDA-approved prescribing information for hormone therapy products, these include clot risk, stroke risk, and for combined estrogen-progestogen therapy, a change in breast cancer risk over time.

The Bottom Line

According to FDA.gov, the FDA does not have separate hormone therapy guidance for younger or older women. All age-related differences in clinical practice come from the judgment of a qualified prescriber, not FDA rules. Your personal history, your symptoms, and your cardiovascular risk profile may matter more than age alone — consult a qualified prescriber for guidance specific to your situation.